Table 3.
Drug resistance profiles distribution among MTBC sublineages.
| MTBC Lineages | Antibiotics | |||
|---|---|---|---|---|
| Rifampicin | Isoniazid | MTBC (Isoniazid + rifampicin resistance) | Susceptible to all drug tested | |
| LAM* | 5 (3.4%) | 33 (22.6%) | 45 (30.8%) | 63 (43.1%) |
| Haarlem* | 5 (4.9%) | 14 (13.7%) | 23 (22.5%) | 60 (58.8%) |
| S* | 1 (2.6%) | 5 (12.8%) | 4 (10.3%) | 29 (74.4%) |
| X* | 1 (6.6%) | 2 (13.33%) | 4 (26.66%) | 8 (53.3%) |
| Beijing | 1 (25%) | — | — | 3 (75%) |
| Ghana | — | — | — | 2 (100%) |
| Delhi | 1 (50%) | 1 (50%) | — | |
| New | — | — | — | 1 (100%) |
| Total | 14 (4.5%) | 54 (17.4%) | 77 (24.48%) | 166 (53.4%) |
320 isolates with complete profiles were included; *indicates statistically significant differences (p < 0.05). For this analysis, we exclude the nine strains of the L4 lineages without a sublineage assignment.